Welcome to the website of
The Blue Ridge Institute for Medical Research (BRIMR)
an independent non-profit organization founded in 2006
This site provides access to two unique BRIMR datasets:
- Authoritative annual rankings of NIH funding to individual researchers and academic institutions; and
- A comprehensive list of the chemical, pharmacological, and clinical characteristics of all protein-kinase inhibitor drugs approved by the FDA.
We are proud to make these data available as resources for the scientific community.
The 2023 federal fiscal year is now underway. It began on 1 October 2022 and will end on 30 September 2023. We anticipate that NIH will release its final summary of 2023 awards in late December. BRIMR will then post a modified version of the NIH data for a 4-week period of public review, likely during January-February 2024, and shortly thereafter will release our 2023 rankings.
Public review of the 2022 data ended on 5 February 2023 and our tallies are now final. We thank the more than 120 individuals and institutions whose input helped ensure accuracy of our results. You can access comprehensive data on the allocation of 2022 NIH awards here.
Complete data for 2006-2021 have also been posted and can be accessed in the navigation menu at the top of each page.
Protein Kinase Inhibitors
There are 74 FDA-approved small molecule protein kinase inhibitors as of 12 February 2023. View them here.